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Neurodegeneration
Deborah Chiabrando*†, Veronica Fiorito†, Sara Petrillo and Emanuela Tolosano
Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin,
Italy
Heme (iron-protoporphyrin IX) is an essential co-factor involved in several biological
processes, including neuronal survival and differentiation. Nevertheless, an excess
of free-heme promotes oxidative stress and lipid peroxidation, thus leading to cell
death. The toxic properties of heme in the brain have been extensively studied
during intracerebral or subarachnoid hemorrhages. Recently, a growing number of
neurodegenerative disorders have been associated to alterations of heme metabolism.
Hence, the etiology of such diseases remains undefined. The aim of this review is to
highlight the neuropathological role of heme and to discuss the major heme-regulated
pathways that might be crucial for the survival of neuronal cells. The understanding
of the molecular mechanisms linking heme to neurodegeneration will be important for
therapeutic purposes.
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INTRODUCTION
Neurodegeneration is a complex process leading to the progressive and selective loss of neurons.
Mitochondrial dysfunction, oxidative stress, protein aggregation and endoplasmic reticulum stress
are well established pathways driving the neurodegenerative process (Lansbury and Lashuel, 2006;
Lin and Beal, 2006; Xiang et al., 2017; Morris et al., 2018). Recent data suggest that iron and heme
metabolism dysfunction may also play a crucial role. The involvement of iron in neurodegeneration
has been well documented (Levi and Finazzi, 2014; Mena et al., 2015; Stockwell et al., 2017)
and iron chelation has been proposed as a therapeutic option (Ward et al., 2015; Ashraf et al.,
2018). Moreover, several neurodegenerative disorders have been associated to dysfunction of heme
metabolism, thus supporting a crucial role for heme in the pathogenesis of such diseases.
The neurotoxicity of heme is evident during intracerebral or subarachnoid hemorrhages. In
these pathological conditions, large amount of hemoglobin and heme are released in the brain
promoting oxidative stress, lipid peroxidation, inflammatory response and finally cell death (Righy
et al., 2016). To counteract the toxic effects exerted by hemoglobin and heme, human cells have
evolved several detoxification mechanisms. During brain injury, the plasma proteins Haptoglobin
and Hemopexin have proved to be protective against free hemoglobin and heme as primary
scavenger systems (Hahl et al., 2013; Ma et al., 2016). Moreover, the induction of the heme-
degrading enzyme heme oygenase-1 (HMOX1) in the brain has been reported in intracerebral and
subarachnoid hemorrhage, and other neurodegenerative conditions (Panahian et al., 1999; Wang
and Doré, 2007; Guan et al., 2009; Gozzelino, 2016).
Hemoglobin-derived heme is not the only form of heme that the nervous system can handle.
Endogenously synthesized heme is also deleterious if not properly managed. Heme synthesis
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is an endogenous and essential process occurring in almost
all tissues, including the nervous system (Smith et al., 2011;
Gozzelino, 2016). Heme is endogenously synthesized to regulate
a plethora of biological processes that may be particularly
relevant in the nervous system. Among them, heme regulates
energy production, ion channels, gene expression and microRNA
processing (Smith et al., 2011). For these reasons, heme is
essential for neuronal survival and differentiation. Recent data
clearly indicate that the amount of intracellular heme available
for regulatory functions (the so called “Heme Regulatory Pool”
or “Labile Heme”) is determined by the balance between
heme synthesis, catabolism, import and export (Chiabrando
et al., 2014b; Reddi and Hamza, 2016). The identification
of a growing number of neurodegenerative disorders due to
mutations in genes involved in heme metabolism strongly
support the idea that the control of labile heme is crucial to avoid
neurodegeneration. How heme drives the neurodegenerative
process is still incompletely understood. However, it is becoming
clear that heme neurotoxicity could be only partially explained by
the release of toxic iron.
Here, we provide an overview of heme-related
neurodegenerative disorders. Moreover, we discuss the potential
mechanisms leading to heme neurotoxicity. We believe that the
understanding of these mechanisms will be essential in the future
to identify novel therapeutic targets.
NEURODEGENERATIVE DISORDERS
CAUSED BY HEME METABOLISM
DYSFUNCTIONS
The physiological relevance to control labile heme in the
nervous system is highlighted by the identification of
neurodegenerative disease-causing mutations in genes
involved in heme metabolism. Indeed, mutations in genes
involved in heme biosynthesis are responsible for neuropathic
Porphyrias and Friederich Ataxia; mutations in the heme
importer FLVCR2 have been found in Fowler Syndrome;
mutations in the heme exporter FLVCR1 cause Posterior
Column Ataxia and Retinitis Pigmentosa, non-syndromic
Retinitis Pigmentosa and Hereditary Sensory and Autonomic
Neuropathies (Figure 1). However, the molecular mechanisms
underlying heme neurotoxicity are still unclear. Below, we
summarize the major clinical features and the molecular genetics
of these rare disorders.
Neurodegenerative Disorders Due to
Defects in Heme Synthesis
Heme synthesis is a well characterized and ubiquitous
process that involves eight enzymatic steps. Briefly, ALAS1
(δ-aminolevulinic acid synthase 1) catalyzes the condensation
of succynil-CoA and glycine in the mitochondrial matrix, to
form δ-aminolevulinic acid (ALA). ALA is transported into the
cytosol where it is converted to coproporphyrinogen III through
a series of enzymatic reactions. Then, coproporphyrinogen III
is translocated back into mitochondria for the final steps of
heme synthesis (Chiabrando et al., 2014a). Mutations in each
gene involved in the heme biosynthetic pathway are responsible
for a group of rare disorders collectively named porphyrias
(Besur et al., 2014; Ramanujam and Anderson, 2015). The
partial deficiency of these enzymes results in reduced heme
synthesis and accumulation of toxic porphyrin precursors in
multiple organ systems, including the skin, liver and nervous
system. Here we focus on neuropathic porphyrias which
are associated with neurologic manifestations. Furthermore,
defects in the last steps of heme synthesis have been reported
in Friederic Ataxia (Schoenfeld et al., 2005; Huang et al.,
2009).
Neuropathic Porphyrias
The most common neurologic manifestations in neuropathic
Porphyrias are a combination of autonomic and peripheral
neuropathy. The autonomic neuropathy is characterized by
abdominal pain, tachycardia, hypertension, constipation and
nausea. The peripheral neuropathy is predominantly a motor
axonal neuropathy leading to muscle pain and weakness.
Sensory neuropathy is manifested as neuropathic pain and distal
paraesthesiaes. The central nervous system (CNS) may also be
affected, leading to psychosis, anxiety, depression and seizures.
Porphyric neuropathies are characterized by relative quiescent
phases followed by acute neurovisceral attacks involving
severe abdominal pain, peripheral neuropathies and psychiatric
disturbances. Such attacks are often exacerbated by external
stimuli (drugs and hormones) that induce endogenous heme
synthesis thus leading to an increase of toxic heme precursors
(Albers and Fink, 2004; Simon and Herkes, 2011; Tracy and Dyck,
2014). Neuropathic Porphyrias include delta-aminolevulinate
dehydratase deficiency, acute intermittent porphyria, hereditary
coproporphyria and variegate porphyria.
Delta-aminolevulinate dehydratase deficiency (ALAD
deficiency; OMIM: #612740) is the only type of neuropathic
porphyria with an autosomal recessive mode of inheritance.
ALAD deficiency is an extremely rare disorder with childhood
onset and severe neurologic implications. ALAD deficiency is
caused by mutations in the gene encoding the second enzyme
in the heme biosynthetic pathway. These mutations cause
almost complete lack of ALAD activity and patients excrete a
large amount of ALA into urine (Ramanujam and Anderson,
2015).
Acute intermittent porphyria (AIP; OMIM: #176000) is an
autosomal dominant disorder with incomplete penetrance. It is
the most common type of neuropathic porphyria. AIP is caused
by mutations in the hydroxymethylbilane synthase (HMBS) gene,
resulting in the partial deficiency of porphobilinogen deaminase
(PBGD). PBGD is the third enzyme in the heme biosynthetic
pathway and its reduced activity leads to the accumulation and
urine excretion of ALA and porphobilinogen (PBG) (Pischik and
Kauppinen, 2015; Ramanujam and Anderson, 2015).
Hereditary coproporphyria (HCP; OMIM: #121300)
is an autosomal dominant disorder with incomplete
penetrance. HCP results from mutations in the gene encoding
coproporphyrinogen oxidase (CPOX). CPOX represents the sixth
enzyme in the heme biosynthetic pathway. Its partial deficiency
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FIGURE 1 | Neurodegenerative disorders associated to heme metabolism dysfunction. Schematic representation of the main pathways involved in the regulation of
intracellular labile heme: heme synthesis, heme incorporation into hemoproteins, heme degradation, heme export and import. The picture highlights rare
neurodegenerative disorders directly associated to heme metabolism dysfunction: defective heme biosynthesis causes neuropathic porphyria and is observed in
FRDA; defective heme export (FLVCR1 mutations) is responsible for PCARP, RP and HSAN. For simplicity, these disorders have been depicted near FLVCR1a;
however, the specific contribution of FLVCR1a and FLVCR1b to these disorders still remains to be addressed. Finally, defective heme import (FLVCR2 mutations)
leads to the Fowler syndrome. Alteration of heme incorporation into hemoproteins and heme degradation have not been directly associated to a specific
neurodegenerative disorder. However, we cannot exclude a role for these pathways in neurodegeneration.
causes the accumulation of ALA, PBG and coproporphyrin III
(Horner et al., 2013; Ramanujam and Anderson, 2015).
Variegate porphyria (VP; OMIM: #176200) is an autosomal
dominant disorder with incomplete penetrance. VP is due to
mutations in the gene encoding protoporphyrinogen oxidase
(PPOX). PPOX catalyzes the oxidation of protoporphyrinogen IX
to form protoporphyrin IX and its partial deficiency causes the
elevation of plasma porphyrins (Horner et al., 2013; Ramanujam
and Anderson, 2015).
The clinical presentation is generally milder in HCP and VP
compared to AIP and ALAD deficiency.
The etiology of the neurological manifestations in neuropathic
porphyrias remained undefined for long time. Nowadays, two
major mechanisms have been proposed to contribute to the nerve
failure: direct neurotoxicity of the porphyrin precursors and
mitochondrial dysfunction (Lin et al., 2011).
Friederich Ataxia
Friederich Ataxia (FRDA; OMIM #229300) is a progressive
neurodegenerative disease usually associated with
cardiomyopathy and diabetes. Although a rare disorder, FRDA
represents the most frequent type of inherited ataxia. FRDA is
characterized by progressive gait and limb ataxia, dysarthria,
areflexia, loss of vibratory and position sense, and a progressive
motor weakness of central origin. Neurodegeneration first affects
the dorsal root ganglia (DRG) but then involves spinal cord,
peripheral nerves and cerebellum (Marmolino, 2011; Bürk,
2017).
Frontiers in Neuroscience | www.frontiersin.org 3 October 2018 | Volume 12 | Article 712
fnins-12-00712 October 5, 2018 Time: 19:9 # 4
Chiabrando et al. Heme and Neurodegeneration
FRDA is an autosomal recessive disorder caused by the
abnormal expansion of the GAA triplet in the first intron of
FRATAXIN (FXN) gene (Campuzano et al., 1996). FXN function
remained elusive for long time. FXN is a mitochondrial iron
chaperone involved in iron–sulfur (Fe–S) clusters and heme
biosynthesis. Here we focus on the role of FXN on heme
biosynthesis and readers are referred to more comprehensive
reviews on the role of FXN in Fe–S clusters biosynthesis
(Stemmler et al., 2010; Martelli and Puccio, 2014; Braymer
and Lill, 2017; Rouault and Maio, 2017). FXN delivers iron to
Ferrochelatase (FECH) (Yoon and Cowan, 2004), the enzyme
responsible for the insertion of iron into protoporphyrin IX.
Structural studies on the interaction between FXN and FECH
shed light on the mechanism of iron delivery between them
(Bencze et al., 2007; Söderberg et al., 2016). Evidences of
defective heme biosynthesis have been reported in both cellular
and mouse models of FXN deficiency as well as in FRDA
patient-derived cells. Collectively these studies showed decreased
expression of enzymes involved in the heme biosynthetic
pathway (Schoenfeld et al., 2005; Huang et al., 2009), induction of
HMOX1 (Huang et al., 2009), increased cellular protoporphyrin
IX levels (Schoenfeld et al., 2005) and reduced heme content
(Schoenfeld et al., 2005; Huang et al., 2009). Although
the majority of these experiments have been performed in
different cell and tissue types, it is conceivable that these
findings can be translated to the nervous system. Fe-S clusters
and heme biosynthesis are the two major iron consuming
processes in mitochondria. Therefore, reduced iron utilization
for Fe–S clusters and heme biosynthesis contributes to iron
accumulation observed in FRDA (Huang et al., 2009). Moreover,
mitochondrial iron accumulation in FRDA was reported to
be due to heme-dependent upregulation of mitoferrin-2, a
mitochondrial iron importer (Martelli et al., 2015). Both
Fe–S clusters and heme are essential cofactors of the electron
transport chain required for energy production. Indeed, FXN
deficiency finally causes mitochondrial dysfunction, that actively
contributes to the disease pathogenesis (Lodi et al., 1999; Martelli
et al., 2015; Chiang et al., 2018).
Several yeast and mouse models of FXN deficiency have been
generated (Perdomini et al., 2013). These models have been
extremely useful to understand the molecular mechanisms of
neurodegeneration associated to FXN loss and to test therapeutic
approaches for the disorder.
Neurodegenerative Disorders Due to
Defects in Heme Import
The import of heme inside the cell is achieved through
multiple transporters: the heme responsive gene 1 (HRG1),
the Heme carrier protein 1/Proton-coupled folate transporter
(HCP1/PCFT) and the Feline leukemia virus subgroup C receptor
2 (FLVCR2).
The role of HRG1 in the import of heme is well
established (Rajagopal et al., 2008; White et al., 2013).
HRG1 is highly expressed in the brain and its transient
downregulation in zebrafish leads to hydrocephalus and yolk
tube malformations suggesting an important role for HRG1
in neurodevelopment (Rajagopal et al., 2008). Conversely, the
substrate-specificity of HCP1 and FLVCR2 have been debated.
HCP1 was initially identified as a heme importer (Shayeghi et al.,
2005). Nevertheless, Qiu A. et al. reported that HCP1 is a folate
transporter implicated in hereditary folate malabsorption (Qiu
et al., 2006). However, evidences suggest that the heme import
function of HCP1 could be relevant in some cell types or in
particular physiologic or pathologic situations (Chiabrando et al.,
2014b). Because of the low expression level of HCP1 in the brain,
the role of HCP1 in the import of heme in the nervous system is
likely marginal.
FLVCR2 is a member of the major facilitator superfamily
(MFS) of transporters (Pao et al., 1998; Law et al., 2008) initially
proposed as a calcium-chelate transporter (Meyer et al., 2010).
Subsequent studies revealed that FLVCR2 is an importer of heme
(Duffy et al., 2010). FLVCR2 is ubiquitously expressed. In the
nervous system, FLVCR2 is widely expressed throughout the
brain and spinal cord (Duffy et al., 2010; Meyer et al., 2010).
However, FLVCR2 expression and subcellular localization still
remain to be investigated in detail due to the lack of a specific
antibody. Among all these heme importers, FLVCR2 is the only
gene directly associated to a neurodegenerative disorder, the
Fowler Syndrome. Therefore, the discussion below is focused
exclusively on this disease.
Fowler Syndrome
Fowler syndrome, also known as Proliferative Vasculopathy,
Hydrancephaly Hydrocephaly syndrome (PVHH; OMIM
#225790), is a rare neurodegenerative disorder. The hallmark
of the disease is the presence of proliferative glomerular
vasculopathy in the CNS associated with severe hydrocephaly,
ventriculomegaly, cortical thinning and hypoplastic cerebellum.
Secondary features are hypokinesia and joint contractures
(Meyer et al., 2010; Williams et al., 2010; Kvarnung et al., 2016).
It is still unclear whether the proliferative vasculopathy is the
primary or secondary event in the disease pathogenesis. Massive
endothelial cells proliferation might be the first event leading
to adjacent tissue damage, calcification and neuronal cells loss.
Otherwise, proliferative vasculopathy might be a consequence of
neurodegeneration (Meyer et al., 2010). The Fowler syndrome
is characterized by early prenatal onset and is incompatible
with life in most cases (Lalonde et al., 2010; Meyer et al., 2010;
Thomas et al., 2010; Williams et al., 2010). Recently, two cases of
survival beyond infancy have been reported. These patients were
characterized by severe intellectual and neurologic disability
(Kvarnung et al., 2016).
The Fowler syndrome is an autosomal recessive disorder
caused by mutations in the FLVCR2 gene (Meyer et al., 2010).
Different kinds of mutations in the FLVCR2 gene have been
reported (Lalonde et al., 2010; Meyer et al., 2010; Thomas et al.,
2010; Kvarnung et al., 2016), including missense and nonsense
mutations, deletions and insertions. Homology modeling of
FLVCR2 structure suggests that the missense mutations related
with Fowler syndrome affect transmembrane domains that may
modify the channel proper function or folding (Radio et al.,
2018). It has been proposed that the mutations might lead to
alteration of heme-iron metabolism. However, this is merely an
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hypothesis since in vitro or in vivo evidences are still lacking.
The generation of appropriate in vitro and in vivo model systems
will be important to investigate the molecular mechanisms
underlying Fowler syndrome.
Neurodegenerative Disorders Due to
Defects in Heme Export
The export of heme is mediated by two widely expressed proteins:
the ATP binding cassette subfamily G member 2 (ABCG2) and
the Feline Leukemia Virus Subgroup C Receptor 1 (FLVCR1).
Besides heme, ABCG2 is involved in the transport of a variety
of substrates: urate, chemotherapeutics, antibiotics, xenobiotics
and food metabolites (Krishnamurthy and Schuetz, 2006). In
the nervous system, ABCG2 is mainly located on the luminal
side of endothelial cells (ECs) (Krishnamurthy and Schuetz,
2006), suggesting an important role for ABCG2 in the blood-
brain-barrier to protect brain from drugs. Furthermore, ABCG2
has been implicated in brain protection following ischemic
reperfusion injury (Shin et al., 2018) and in Alzheimer’s disease
(Xiong et al., 2009; Zeng et al., 2012; Shen et al., 2010).
However, the relevance of ABCG2-mediated heme efflux to
neurodegeneration still remains to be elucidated.
Feline Leukemia Virus Subgroup C Receptor 1 (FLVCR1) is
a member of the MFS of transporters (Pao et al., 1998; Law
et al., 2008), implicated in the transport of heme and other
planar porphyrins (Yang et al., 2010). FLVCR1 gene encodes for
two isoforms: FLVCR1a expressed at the plasma membrane and
FLVCR1b in mitochondria (Chiabrando et al., 2012). FLVCR1
is ubiquitously expressed (Quigley et al., 2004; Keel et al., 2008;
Chiabrando et al., 2012; Fiorito et al., 2014, 2015; Vinchi et al.,
2014; Mercurio et al., 2015; Petrillo et al., 2017). In the nervous
system, Flvcr1 mRNA has been detected in the mouse brain
(neocortex, striatum, hippocampus, and cerebellum), posterior
column of the spinal cord, retina and retinal pigment epithelium.
The highest Flvcr1 mRNA levels have been found in the
retina and spinal cord (Rajadhyaksha et al., 2010; Gnana-
Prakasam et al., 2011). Unfortunately, no information is available
concerning FLVCR1 protein expression levels and localization in
neurons and glia, due to the lack of a reliable antibody against
FLVCR1. Mutations in FLVCR1 gene have been reported in
distinct disorders affecting the sensory nervous system: Posterior
Column Ataxia and Retinitis Pigmentosa, Retinitis Pigmentosa
and Hereditary Sensory and Autonomic Neuropathy, as reviewed
below.
Posterior Column Ataxia and Retinitis Pigmentosa
(PCARP)
PCARP (OMIM: #609033) is a rare neurodegenerative syndrome
characterized by sensory ataxia and retinitis pigmentosa. Sensory
ataxia is a consequence of the degeneration of the posterior
columns of the spinal cord, resulting in loss of proprioception.
Retinitis pigmentosa is due to the progressive degeneration of
photoreceptors in the retina, leading to night blindness and
progressive restriction of the visual field (Higgins et al., 1997;
Rajadhyaksha et al., 2010). PCARP has been described for the first
time in Higgins et al. (1997) as an autosomal recessive disorder
associated with the AXPC1 locus (Higgins et al., 1999). In 2010,
the analysis of three inbreed families of different ethnic origins
revealed that mutations in the FLVCR1 gene were responsible
for the disorder (Rajadhyaksha et al., 2010). In the majority
of cases, PCARP is caused by homozygous mutations in the
FLVCR1 gene (c.361A > G – c.721G > A – c.574T > C –
c.1477G<C) (Rajadhyaksha et al., 2010; Ishiura et al., 2011). The
identified mutations are missense mutations that affect highly
conserved residues in potential transmembrane domains of the
heme exporter. In vitro studies suggest that these mutations result
in the mislocalization of FLVCR1 protein and in the loss of
its heme export function. Compound heterozygous mutations
in the FLVCR1 gene have been also reported in three siblings
(c.1547G > A and c.1593 + 5_ + 8delGTAA) (Shaibani et al.,
2015).
Retinitis Pigmentosa (RP)
Non-syndromic retinitis pigmentosa (RP; OMIM: #268000)
encompasses a group of genetically heterogeneous disorders
characterized by the progressive neurodegeneration of
photoreceptors. RP-associated genes are involved in different
processes: phototransduction, retinal metabolism, tissue
development and maintenance, cellular structure and splicing
(Hartong et al., 2006). Recently, FLVCR1 mutations have
been reported in some patients with retinitis pigmentosa
(RP) without evidences of posterior column degeneration
or cerebellar degeneration (Tiwari et al., 2016; Yusuf et al.,
2018). Interestingly, all the patients carry a specific splice-site
variant in FLVCR1 (c.1092 + 5G > A) in homozygosity or as
compound heterozygosity. Functional studies showed that the
c.1092 + 5G > A mutation interferes with the correct splicing
of FLVCR1 resulting in the skipping of exon 4, the frame-shift
deletion of 68bp and a premature stop codon (Tiwari et al., 2016;
Yusuf et al., 2018).
Hereditary Sensory and Autonomic Neuropathy
(HSAN)
HSANs are a group of neurodegenerative disorders of the
peripheral nervous system mainly characterized by impaired
nociception and autonomic dysfunction. The hallmark of the
disease is the degeneration of sensory neurons, which transmit
information about sensations such as pain, temperature and
touch. The inability to experience pain causes unintentional
self-injuries and chronic ulcerations. Soft tissue infections and
osteomyelitis, often requiring amputations, are common. The
disease is also associated to mild abnormalities of the autonomic
nervous system: swallowing and feeding problems, apnea, gastro-
esophageal reflux and delayed development are variable features
of the disorder (Verpoorten et al., 2006; Rotthier et al., 2012;
Auer-Grumbach, 2013).
HSANs arise from mutations in genes that are crucial
for distinct molecular pathways: sphingolipid-metabolism,
membrane-shaping of organelles, neurotrophin action, DNA
methylation, regulation of ion channels, endoplasmic reticulum
turnover and axonal trafficking and heme metabolism (Rotthier
et al., 2012; Khaminets et al., 2015; Chiabrando et al., 2016;
Tanaka et al., 2016). Recently, mutations in the FLVCR1 gene
have been reported in a subset of HSAN patients. Compound
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heterozygous mutations in FLVCR1 (c.574T > C and c.610del –
c.661C > T and c.1324dup) have been reported (Chiabrando
et al., 2016). Functional studies in patient-derived cells showed
that these mutations reduce heme export activity, enhance
oxidative stress and increase the sensitivity to programmed
cell death (Chiabrando et al., 2016). Finally, Castori et al.
(2017) reported the homozygosity for a previously identified
pc.661C> T variation in a sporadic case with a mixed phenotype
of HSAN, PCARP and acute lymphocytic leukemia.
Due to the limited number of cases described to date, it is very
difficult to understand whether FLVCR1-related PCARP, RP and
HSAN are distinct disorders or rather a single clinical spectrum.
The finding of FLVCR1 mutations in PCARP, RP and HSAN
indicates that heme is particularly required for the survival of
specific subpopulation of neurons. However, the elucidation of
the role of heme in these subpopulations is far to be clearly
understood.
The available mouse models of FLVCR1 deficiency did not
recapitulate the major disease features of HSAN, PCARP or RP.
The targeted disruption of Flvcr1 gene causes embryonic lethality
in two different mouse models. Mice lacking both Flvcr1a and
Flvcr1b die in utero because of a block of erythropoiesis (Keel
et al., 2008). Mice lacking only Flvcr1a die during embryonic
development due to severe hemorrhages, edema and skeletal
malformations (Chiabrando et al., 2012). The downregulation
of FLVCR1 isoforms in zebrafish confirm the essential role
of FLVCR1 isoforms in erythropoiesis and ECs maintenance
(Mercurio et al., 2015).
The discrepancy between the phenotype of these animal
models and the human diseases is likely due to different degree
of Flvcr1a downregulation. Indeed, HSAN patients-derived cells
still expressed FLVCR1a but are characterized by reduced heme
export activity (Chiabrando et al., 2016). Moreover, treatment
of patient-derived cells with Hemopexin, that facilitates heme
export through FLVCR1a (Chiabrando et al., 2016), improved cell
survival. These data clearly indicate that FLVCR1 mutations do
not completely abrogate FLVCR1a function (Chiabrando et al.,
2016). Reasonably, embryonic lethality is expected for patients
carrying null mutations in the FLVCR1 gene.
The reason why the loss of an ubiquitously expressed
heme exporter affects specific sensory modalities (vision,
proprioception and/or nociception) is still unknown. The
development of appropriate cellular and mouse models will help
dissecting the role of FLVCR1 in these disorders.
HEME-REGULATED PROCESSES
CRUCIAL FOR
NEUROURODEGENERATION
In the paragraphs above, we summarized the most relevant
neurodegenerative disorders associated to alterations in heme
metabolism. However, the etiology of such diseases remains
mostly undefined. Heme bears toxic properties due to its
ability to promote iron mediated Fenton’s reaction. This
awareness contributed over the years to underestimate the
importance of iron-independent mechanisms of heme toxicity in
neuronal diseases. The misconception that heme neurotoxicity
is due to iron release from protoporphyrin IX mainly
contributed to the lack of interest in the topic. To stimulate
research in the field, we will discuss the major heme-regulated
pathways that might be relevant during neurodegeneration
(Figure 2).
Heme and Oxidative Stress: Implications
for Neurodegenerative Disorders
Oxidative stress is a condition occurring when the production
of reactive oxygen species (ROS) overcomes the endogenous
antioxidant defenses. Accumulation of ROS causes the oxidative
damage of cellular components, included lipids, proteins and
nucleic acids. As a pro-oxidant molecule, heme can itself promote
oxidative stress, eventually leading to cell death. In particular, due
to its hydrophobic nature, free heme tends to aggregate and bind
to cell membranes. Oxidation of membrane components leads
to increased permeability and altered lipid organization, in turn
promoting cell lysis and death (Schmitt et al., 1993). The redox
activity of heme-derived iron also contributes to the cytotoxic
effects of heme. Indeed, in aqueous phase heme becomes unstable
and releases free iron, responsible for the formation of ROS
via the Fenton’s reaction (Kumar and Bandyopadhyay, 2005).
The CNS is particularly susceptible to oxidative stress due to its
high oxygen consumption rates and weak antioxidant systems.
Consistently, oxidative stress is involved in the pathogenesis
of several neurodegenerative disorders as Parkinson’s disease,
Alzheimer’s disease, Huntington’s disease and FRDA (Schulz
et al., 2000; Calabrese et al., 2005; de Vries et al., 2008; Li
et al., 2013; Puspita et al., 2017). Increased ROS levels have
been observed also in HSAN patient-derived cells (Chiabrando
et al., 2016; Castori et al., 2017). To counteract the toxic
effects exerted by ROS accumulation, human cells have evolved
several detoxification mechanisms. In particular, the primary
defense systems against ROS consists of oxidant-inactivating
enzymes, such as superoxide dismutase or HMOX1, and
endogenous antioxidants, including glutathione and thioredoxin
(Li et al., 2013). The transcriptional response to oxidative stress is
mediated by a cis-regulatory element known as ARE (antioxidant
response element) found in the promoters of genes codifying for
antioxidant proteins. Nuclear factor E2-related factor 2 (Nrf2)
is the major trans-acting factor responsible for the activation
of gene transcription through its binding to the AREs (Nguyen
et al., 2009). Notably, alterations in Nrf2 signaling pathway
have been found in Parkinson’s disease, Alzheimer’s disease, and
Huntington’s disease (PMID: 18824091) as well as in a cardiac
mouse model of FRDA (Anzovino et al., 2017). Several proteins
and kinases modulate the Nrf2 pathway at various levels to
ensure a tight control of its activity. Among these regulators, BTB
domain and CNC homolog 1 (Bach1) acts as a repressor of Nrf2
activity by competing with Nrf2 for ARE binding sites. Notably,
the activity and localization of Bach1 is regulated by heme (Sun
et al., 2004; Suzuki et al., 2004; Marro et al., 2010), thus suggesting
that alterations in heme homeostasis might affect the Nrf2-Bach1
axis and the cell ability to respond to the oxidative insult. This
mechanism could be particularly relevant in the progression
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FIGURE 2 | Potential mechanisms leading to neurodegeneration. The picture summarizes the major heme-regulated processes that might be relevant during
neurodegeneration. The alteration of intracellular labile heme may affect cell proteostasis, oxidative phosphorylation, ion channels function and/or induce oxidative
stress, leading to neurodegeneration.
of neurodegenerative diseases, which is indeed exacerbated by
oxidative stress. Hence, oxidative stress might exert neurotoxicity
also by impairing the ubiquitin-proteasome system, as found in
Parkinson’s disease (PD) where a decreased protein clearance
rate due to elevated ROS results in the accumulation of alpha-
synuclein (Hashimoto et al., 1999; McNaught and Jenner, 2001).
The Role of Heme in Cellular
Proteostasis: Implications for
Neurodegenerative Disorders
The maintenance of protein homeostasis, also called proteostasis,
is essential for cell function and survival (Hartl et al., 2011;
Morimoto and Cuervo, 2014; Kaushik and Cuervo, 2015). The
constant control of cellular proteostasis requires the proper
activity of two main cellular components (Kaushik and Cuervo,
2015). On one hand, the activity of chaperones is fundamental
to correct protein misfolding eventually occurring during
protein synthesis, assembly in three-dimensional and functional
structures and trafficking. On the other hand, protein clearance
mechanisms mediate the removal of irreversibly misfolded
proteins. In particular, this second purpose is achieved most
prominently through two molecular systems: the ubiquitin-
proteasome system (UPS) and the autophagy system. These
systems are able to sense disturbances in the proteome and to
be rapidly activated, thus exerting a constant protein quality
control. In this way, the proteostasis network ensures the cell the
ability to adapt to environmental changes and transitory stress.
Reduced proteostasis capacity may lead to the accumulation of
misfolded proteins, which form cytotoxic aggregates (Morimoto
and Cuervo, 2014). Deficiencies in the machinery of protein
homeostasis promote the onset and progression of several
human pathologies, including neurodegenerative diseases (Hartl
et al., 2011). For instance, deposits of aberrant proteins such
as tau and α-synuclein, have been associated with dementia
and Parkinson’s disease. The use of proteasome inhibitors
as Bortezomib in cancer therapy has been shown to induce
peripheral neuropathy as a prominent side effect (Alé et al., 2014;
Kaplan et al., 2017). Moreover, an impairment of mitochondrial
turnover via selective autophagy has been found in Parkinson’s
disease (Andreux et al., 2013) and in sensory neuropathy
(Khaminets et al., 2015). In addition to the above described
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classical proteostasis network, which assures the quality control
of de novo synthetized cytosolic proteins, organelle-specific
systems can be activated in response to proteotoxic stress
occurring in specific subcellular compartments (Kaushik and
Cuervo, 2015). These signaling pathways include the unfolded
protein response (UPR) of the endoplasmic reticulum (ER)
and mitochondria. In particular, the presence of unfolded
proteins in the ER promotes the activation of three ER-
resident transmembrane proteins: PERK (protein kinase RNA
(PKR)-like ER kinase), ATF6 (activating transcription factor-
6) and IRE1α (inositol-requiring enzyme-1α). The signaling
cascade mediated by downstream effectors leads to an overall
translational attenuation as well as enhanced transcription of
ER chaperons. A similar mechanism has been described in
mitochondria, which are particularly exposed to stressors that
can trigger protein damage. Notably, alterations in the UPR
machinery are involved in the pathogenesis of neurodegenerative
diseases such as Alzheimer’s disease, Parkinson’s diseases,
Huntington’s disease and prion disease, which are indeed
characterized by accumulation and aggregation of misfolded
proteins (Scheper and Hoozemans, 2015; Xiang et al., 2017).
Finally, mutations in genes associated with ER function have
been described in neurodegenerative disorders as Charcot-Marie-
Tooth disease (CMT), hereditary neuropathies with proximal
dominant involvement (HMSN-P) and amyotrophic lateral
sclerosis (Beetz et al., 2013; Tsai et al., 2014; Yagi et al., 2016;
Murakami et al., 2017).
Growing evidences indicate that the alteration of intracellular
heme levels affects proteostasis. For instance, heme directly
binds and inhibits the proteasome machinery promoting the
formation of perinuclear “aggresomes” of ubiquitinated proteins
(Vallelian et al., 2015). In particular, Vallelian et al. (2015)
analyzed changes in protein expression upon heme treatment in
mouse embryo fibroblasts (MEF) isolated from wild type and
mice lacking HMOX1 (Hmox1-null mice). The study of the
proteome in Hmox1-null MEF by mass spectrometry revealed
a specific signature characterized by a strong upregulation
of networks related to the response to unfolded proteins.
These data suggest that excessive intracellular heme can trigger
proteostasis disruption. In particular, heme overload correlates
with accumulation of ubiquitinated proteins, thus indicating
a reduced protein degradation capacity in heme-stressed
cells (Vallelian et al., 2015). Consistent with these previous
observations, the formation of protein aggregates has been
described in macrophages during heme stress (Vasconcellos et al.,
2016). In particular, cell treatment with increasing concentration
of heme leads to the formation of aggresome-like induced
structures (ALIS), which are characterized by the presence
of p62/SQSTM1 (sequestosome-1) and ubiquitinated proteins.
Importantly, the pre-treatment with ROS scavengers completely
abolishes heme-induced ALIS formation in bone marrow-
derived macrophages, thus indicating that ROS generation
has a key role in this process (Vasconcellos et al., 2016). In
addition, p62 is an inhibitor of the Nrf2 repressor Keap1 (Kelch-
like ECH-associated protein 1). Therefore, the heme-induced
sequestration of p62 in ALIS might affect the Nrf2-Keap1 axis
(PMID: 24011591), interfering with the antioxidant response
mediated by Nrf2-regulated genes. Enhanced ROS production
and proteasome inhibition thus represent two different activities
of heme, which turned out to be extremely cytotoxic in conditions
of heme excess. These findings, taken together, point out a novel
model of heme toxicity mediated by accumulation of damaged
proteins and disruption of cellular proteostasis.
Another evidence of the proteotoxic effect mediated by
heme comes from studies on ECs lacking FLVCR1a. The loss
of the heme export way in ECs leads to the accumulation
of endogenously synthetized heme, which in turn triggers
programmed cell death via paraptosis and impairs the angiogenic
process during embryonic development (Petrillo et al., 2017).
Importantly, an altered swollen morphology of the ER as well as
an increased expression of ER stress markers have been described
in ECs isolated from embryos lacking Flvcr1a in endothelial
cells (Petrillo et al., 2017). Interestingly, paraptosis has been
described in neural development and neurodegeneration (e.g.,
amyotrophic lateral sclerosis and Huntington’s disease), in the
ischemic damage and in the context of retina pathophysiology
(Lee et al., 2016).
Although specific studies in neuronal cells are still lacking,
we proposed that similar mechanisms might be relevant
in the nervous system. Therefore, the disruption of cell
proteostasis might be an important mechanisms contributing to
neurodegeneration in conditions of altered intracellular heme
levels.
The Role of Heme in Mitochondria:
Implications for Neurodegenerative
Disorders
An additional mechanism through which heme could potentially
participate to neurodegeneration is through the control of
mitochondrial function. Mitochondrial dysfunction is a common
pathogenetic mechanism of several neurodegenerative disorders.
Particularly, the alteration of mitochondria by different
mechanisms has been proposed as one of the underlying cause
of Parkinson’s disease, Alzheimer’s disease, Huntington’s disease
and amyotrophic lateral sclerosis (Shi et al., 2010; Costa and
Scorrano, 2012; Bennett et al., 2014; Cabezas-Opazo et al., 2015;
Arun et al., 2016; Bose and Beal, 2016).
Heme is a crucial cofactor for cytochromes c and
cytochromes in complexes II, III and IV of the mitochondrial
electron transport chain (ETC) (Kim et al., 2012), thus
modulation of heme metabolism could interfere with oxidative
phosphorylation. Moreover, some of the steps of heme synthesis
occur in mitochondria and initiate by the condensation of
succynil-CoA with glycine. Succynil-CoA is an intermediate
of the TCA cycle, so heme production belongs to the group of
TCA cycle cataplerotic pathways (Frezza et al., 2011; Fukuda
et al., 2017), a set of processes whose function is to avoid
the accumulation of TCA cycle metabolites. Alterations in
heme biosynthesis, consequently, could impair this system
thus altering mitochondrial function. In addition, heme has
been reported to directly or indirectly influence adenosine
triphosphate (ATP) translocation among mitochondria and
cytosol (Sabová et al., 1993; Giraud et al., 1998; Azuma et al.,
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2008) and, therefore, modulation of heme homeostasis could
profoundly affect the mitochondrial contribution to cell energy
supply.
Supporting the role of heme in mitochondrial function,
analyses on ECs demonstrated that alterations in heme
metabolism, in addition to promote lipid peroxidation and
activation of autophagy, induce mitophagy and apoptosis,
indicating mitochondrial dysfunction (Higdon et al., 2012).
Furthermore, we previously reported that loss of FLVCR1 impairs
mitochondrial function in HeLa cells (Chiabrando et al., 2012)
and mitochondrial morphology in human microvascular ECs
(Petrillo et al., 2017).
Considering the role of heme in mitochondria, it is tempting
to speculate that, by affecting mitochondrial function, the
impairment of heme metabolism in neuronal cells could
potentially initiate or sustain processes responsible for neuronal
cells defects and death. Supporting this hypothesis, studies in the
brain of HMBS−/− mice, a model of AIP, showed alterations in
the activity of ETC complexes likely related to the compromised
heme biosynthesis (Homedan et al., 2014). Moreover, it has been
suggested that an energy failure may lead to a defective activity
of the Na/K+ ATPase in the axon, leading to its degeneration
(Lin et al., 2011). Since heme is required for ATP synthesis,
we cannot exclude that heme metabolism could have a role in
this context. Furthermore, defects in mitochondrial iron content,
in the activity of the respiratory chain complexes and in ATP
production have been observed in FRDA (Lodi et al., 1999).
Although these defects in FRDA can be ascribed to alterations
in Fe–S clusters trafficking, the contribution of heme to these
processes cannot be excluded. Finally, in three cases of Fowler
syndrome it was suggested the presence of a defect in complex
III and IV of the ETC (Castro-Gago et al., 1999, 2001), directly
indicating that mitochondrial defects due to alterations in heme
trafficking could be the underlying cause of the neurological
outcomes of this syndrome.
The contribution of mitochondrial dysfunction to PCARP,
HSAN and RP has not been investigated. However, the
implication of heme in these pathologies suggests the
possibility that mitochondrial function could contribute
to them. Notably, in sensory neurons the importance of
heme in mitochondria could be related not only to the
production of ATP, but also to mitochondrial dynamics
(fusion, fission, motility). Mitochondrial dynamics are crucial
for neurotransmission, synaptic maintenance and neuronal
survival. Proper mitochondrial trafficking is particularly
important in neurons as compared to other cell types due to
their exceptional cellular morphology. Indeed, neurons extend
their axons and dendrites for very long distances. Therefore,
the neurons represent an extreme case of mitochondrial
distribution: dysfunctions in mitochondrial distribution that
are not dangerous for other cells, could be fatal for neuronal
survival (Schwarz, 2013). Supporting this concept, compromised
mitochondrial motility has been reported in Alzheimer’s disease
(Cabezas-Opazo et al., 2015), Parkinson’s disease (Yang et al.,
2008; Carelli et al., 2015), Huntington’s disease (Shirendeb et al.,
2011) and in amyotrophic lateral sclerosis (De Vos et al., 2007;
Shi et al., 2010).
In the case of human peripheral nerves or corticospinal
tracts, axons can extend up to a meter, so the population
of sensory neurons could be highly sensitive to defects in
mitochondrial dynamics. Modulation of the cellular labile iron
pool and mitochondrial iron content have been observed in
FXN deficiency in association to alterations in both heme
biosynthesis and OPA1 (mitochondrial dynamin like GTPase)-
mediated mitochondrial fusion (Martelli et al., 2015). Although a
causative link among these phenomena has not been proposed
in FRDA, it is tempting to speculate that the modulation
of iron and heme homeostasis could promote alterations in
mitochondrial dynamics, with deleterious consequences in this
pathology and, more likely, in neurological disorders affecting
sensory neurons.
Heme Regulates Ion Channels:
Implications for Neurodegenerative
Disorders
Emerging evidences suggest that labile heme is a signaling
molecule that impact on the function of various ion channels
involved in neuron excitability. Among them, voltage-gated
K+ channels are a large family of K+ channels that open
on membrane depolarization and contribute to maintain the
resting potential and to determine the shape and frequency of
action potentials in excitable cells (Sahoo et al., 2014). Heme
directly binds to the large-conductance calcium-dependent Slo1
BK channels and Kv1.4 A-type K+ channels. The high affinity
binding of heme to Slo1 BK channels decreases the frequency
of channel opening leading to an inhibition of transmembrane
K+ currents (Tang et al., 2003). Its binding to the N-terminal
domain of the Kv1.4 channels inhibits the fast inactivation of
the channel, thus reducing cellular excitability (Sahoo et al.,
2013).
The activity of several K+ channels is modulated by carbon
monoxide (CO) (Tang et al., 2004) and ROS (Sahoo et al.,
2014; Peers and Boyle, 2015). Heme may also indirectly regulate
the activity of several K+ channels through the generation
of CO and ROS. Indeed, the degradation of heme by HO1
produces iron, biliverdin and CO. Moreover, the released iron
is responsible for the formation of ROS via the Fenton’s
reaction.
An alteration of the activity, function or expression of
diverse K+ channels have been reported in Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease and ataxias (Peers
and Boyle, 2015). As mentioned before, increased ROS is
common to all these neurodegenerative diseases. Oxidative
modulation of diverse K+ channels has been proposed as a
pathogenetic mechansim leading to neurodegeneration. Finally,
several studies highlight a crucial role of K+ channels in
nociception (Busserolles et al., 2016). The identification of
FLVCR1 mutations in patients affected by HSAN (Chiabrando
et al., 2016; Castori et al., 2017) suggests that the alteration of K+
channels activity may explain sensory defects in these patients.
Considering all these data, it is possible to speculate that the
alteration of labile heme may affect the activity of K+ channels,
thus contributing to the neurodegenerative process.
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CONCLUDING REMARKS
The recent identification of several neurodegenerative
disorders due to mutations in genes involved in heme
metabolism highlights a previously unappreciated role for
heme in neurodegeneration. Here, we discussed the potential
mechanisms leading to heme neurotoxicity, thus suggesting
future directions for investigation. The understanding of such
mechanisms might be relevant for several neurodegenerative
disorders. Indeed, alteration of heme metabolism have
been observed also in Alzheimer’s disease, Parkinson’s
disease and other aging-related neurodegenerative disorders
(Atamna and Frey, 2004; Atamna, 2006; Scherzer et al.,
2008; Dwyer et al., 2009; Smith et al., 2011; Hayden et al.,
2015; Sampaio et al., 2017; Santiago and Potashkin, 2017;
Fiorito et al., 2018). In the future, the comprehensive
understanding of the molecular mechanisms linking heme to
neurodegeneration will be potentially important for therapeutic
purposes.
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